Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
EPO-CABG
Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial
1 other identifier
interventional
71
1 country
1
Brief Summary
The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Sep 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedFirst Submitted
Initial submission to the registry
April 4, 2008
CompletedFirst Posted
Study publicly available on registry
April 9, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2009
CompletedResults Posted
Study results publicly available
June 16, 2009
CompletedJune 16, 2009
April 1, 2009
1.4 years
April 4, 2008
March 17, 2009
April 28, 2009
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants Who Had AKI (Acute Kidney Injury)
number of participants who had 50% increase in serum creatinine levels from baseline
at any time within the first 5 days after surgery
Secondary Outcomes (1)
Change in Estimated Glomerular Filtration Rate (eGFR)
during the first 5 days after surgery
Study Arms (2)
EPO group
ACTIVE COMPARATORPlacebo group
PLACEBO COMPARATORInterventions
300 IU/kg of EPO or saline intravenously before surgery
300 IU/kg of normal saline intravenously before surgery
Eligibility Criteria
You may qualify if:
- Patients scheduled for elective CABG over age 18
You may not qualify if:
- Under age 18
- Emergent CABG
- Prior exposure to nephrotoxic drug
- Dialysis patients
- Uncontrolled hypertension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 463-707, South Korea
Related Publications (1)
Nishiwaki H, Abe Y, Suzuki T, Hasegawa T, Levack WM, Noma H, Ota E. Erythropoiesis-stimulating agents for preventing acute kidney injury. Cochrane Database Syst Rev. 2024 Sep 20;9(9):CD014820. doi: 10.1002/14651858.CD014820.pub2.
PMID: 39301879DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Effect of erythropoietin in kidney after cardiac surgery
- Organization
- Seoul National University Bundang Hospital
Study Officials
- PRINCIPAL INVESTIGATOR
Ki Young, Na, MD PhD
Department of Internal Medicine
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 4, 2008
First Posted
April 9, 2008
Study Start
September 1, 2006
Primary Completion
February 1, 2008
Study Completion
February 1, 2009
Last Updated
June 16, 2009
Results First Posted
June 16, 2009
Record last verified: 2009-04